SANTA CRUZ BIOTECHNOLOGY, INC.

PLZF (h2): 293T Lysate: sc-114505

BACKGROUND

Hypermethylated in cancer (HIC-1) was originally identified as a target of p53-induced gene expression. HIC-1 is deleted in the genetic disorder Miller-Dieker syndrome (MDS). The expression of HIC-1 is also frequently suppressed in leukemia and other various cancers due to the hypermethylation of specific DNA regions and the resulting transcriptional silencing. These and other studies indicate that HIC-1 acts as a putative tumor suppressor protein that mediates transcriptional repression. HIC-1 is ubiquitously expressed in adult tissues and its structure is defined by five zinc fingers and an N-terminal broad-complex POZ (or BTB) domain. The BTB/POZ domain mediates homomeric and heteromeric POZ-POZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including BCL-6 and the promyelocytic leukemia zinc finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. Conversely, HIC-1 does not interact with components of the HDAC complex, suggesting that HIC-1-induced transcriptional repression is unassociated with the POZ/BTB domain.

REFERENCES

1. Wales, M.M., et al. 1995. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1: 570-577.
2. Ahmad, K.F., et al. 1998. Crystal structure of the BTB domain from PLZF. Proc. Natl. Acad. Sci. USA 95: 12123-12128.
3. David, G., et al. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16: 2549-2556.
4. Huynh, K.D., et al. 1998. The Bcl-6 POZ domain and other POZ domains interact with the corepressors N-CoR and SMRT. Oncogene 17: 2473-2484.
5. Wong, C.W., et al. 1998. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARα, and Bcl-6. J. Biol. Chem. 273: 27695-27702.
6. Guerardel, C., et al. 1999. Evolutionary divergence in the broad complex, tramtrack and bric-a-brac/pox viruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. FEBS Lett. 451: 253-256.
7. Deltour, S., et al. 1999. Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and γFBP-B. Proc. Natl. Acad. Sci. USA 96: 14831-14836.
8. Denne, M., et al. 2007. Physical and functional interactions of human endogenous retrovirus proteins NP9 and Rec with the promyelocytic leukemia zinc finger protein. J. Virol. 81: 5607-5616.
9. Rho, S.B., et al. 2007. TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF. J. Cell. Biochem. 101: 57-67.

CHROMOSOMAL LOCATION

Genetic locus: ZBTB16 (human) mapping to 11q23.2.

PRODUCT

PLZF (h2): 293T Lysate represents a lysate of human PLZF transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

PLZF (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive PLZF antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-tranfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.